Table 6.
Characteristics of Cushing’s disease patients who developed hypokalemia during ketoconazole treatment.
| ID | Dose (mg) | HK episodes | K value | Disease control | BP control | Previous medications in use |
|---|---|---|---|---|---|---|
| 9 | 1,200 | 7 | 3.3 3.3 3 2.8 2.8 2.8 3 |
No No No No Partial No No |
High High Normal Normal Normal High Normal |
HCTZ (suspension) enalapril, spironolactone, PPL, amlodipine, cabergoline, mitotane |
| 15 | 600 | 1 | 3.2 | Yes | Normal | HCTZ |
| 16 | 1,000 | 1 | 2.8 | Yes | High | Spironolactone, furosemide, enalapril, chlorthalidone, simvastatin |
| 8 | 600 | 1 | 3.4 | Yes | Normal | HCTZ |
| 10 | 800 | 1 | 3.1 | No | High | HCTZ |
| 14 | 800 | 1 | 3.3 | No | Normal | HCTZ and captopril |
| 19 | 1,200 | 1 | 2.9 | No | Unavailable | Amlodipine, atenolol, losartan, hydralazine, spironolactone |
| 25 | 400 | 1 | 3.2 | Partial | High | HCTZ |
| 28 | 1,200 | 3 | 2.9 2.6 3.3 |
Partial Partial No |
High High High |
Losartan, chlorthalidone, spironolactone, hydralazine |
| 27 | 400 400 600 |
3 | 3.1 3.4 3.4 |
Yes No Yes |
Normal Normal Normal |
Enalapril and HCTZ |
HK, hypokalemia; HCTZ, hydrochlorothiazide; PPL, propranolol.